Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pevion, CSL in therapeutic Candida vaccine agreement
PEV7 is a therapeutic vaccine based on a protein antigen, Sap2, a key virulence factor of vulvovaginal candidiasis, presented on the surface of virosomes. The companies have also
PEV7 is a therapeutic vaccine based on a protein antigen, Sap2, a key virulence factor of vulvovaginal candidiasis, presented on the surface of virosomes. The companies have also
The funding for the initiative will be provided by SAIC through its Malaria Vaccine Production and Support Services contract with the National Institute of Allergy and Infectious Diseases
Tesamorelin is intended as a treatment for excess abdominal fat in HIV-infected patients with lipodystrophy. Earlier in December 2010, Theratechnologies has given license to an affiliate of Sanofi
Orphenadrine is indicated as an adjunct to rest, physical therapy and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. The company expects to
The approval allows Roche to use Tarceva as a first-line monotherapy in people with locally advanced or metastatic NSCLC with EGFR (epidermal growth factor receptor) activating mutations. In
The trial aims to investigate the safety and efficacy of KUR-211 as an adjunct to standard of care in patients suffering from diabetic foot ulcers. The study investigates
The company has posted a net loss of $11.64m for the second quarter of 2011, compared to net income of $6.88m for the same period in 2010. Horizon
The original agreement was signed in April 2010 to apply Anacor’s boron chemistry to identify new medicines to treat malaria. As per the expanded agreement, MMV will provide
The new Omega-3 with Vitamin D3 capsules now comprise 830 IUs of vitamin D3 and continue to provide more than 1,000mg of concentrated EPA and DHA fatty acids.
The trial aims to investigate the safety and preliminary efficacy of MOR202 in patients with relapsed or refractory multiple myeloma. In the trial, the patients with relapsed or